Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection

  1. 1Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA

Abstract

Severe acute respiratory syndrome 2 (SARS-CoV-2), the single-stranded RNA virus responsible for Coronavirus Disease 2019 (COVID-19), continues to circulate globally, with the emergence of antigenically distinct variants posing ongoing challenges to vaccine effectiveness. In particular, Omicron subvariants harbor numerous mutations in the receptor-binding domain (RBD), which contribute to immune evasion and reduced susceptibility to neutralization by antibodies. Previous COVID-19 mRNA vaccines encoding the spike (S) protein of the ancestral SARS-CoV-2 or early variants of concern have demonstrated limited efficacy against Omicron subvariants, underscoring the need for next-generation vaccines capable of eliciting broad-spectrum neutralizing antibodies against Omicron and providing cross-protection against antigenically distinct variants. In this study, we designed an mRNA vaccine encoding a conserved Omicron-S backbone incorporating the JN.1 RBD (S-JN1-RBD), formulated the mRNA with lipid nanoparticles (LNPs), and evaluated its neutralizing activity and protective efficacy. This mRNA-LNP formulation exhibited an appropriate particle size and high thermal stability. It elicited cross-reactive antibodies against S proteins harboring diverse Omicron-RBDs, resulting in broad neutralizing activity against multiple pseudotyped and authentic SARS-CoV-2 Omicron subvariants. Importantly, this vaccine conferred cross-protection against challenge with the heterologous, antigenically divergent XBB.1.5 Omicron subvariant in human angiotensin-converting enzyme 2-transgenic mice. Furthermore, passive transfer of immune sera protected mice against infection with the Omicron-KP.3 subvariant, providing additional evidence of the vaccine’s broad protective potential. These findings underscore the potential of the designed mRNA immunogen to elicit broad-spectrum neutralizing antibody responses and to confer cross-protection against diverse and emerging SARS-CoV-2 subvariants.

Related

  1. Controlled human infection with Plasmodium falciparum-infected mosquito bites elicits antibodies against mosquito salivary protein SG1L3
    Carolina M. Andrade, Renate C. van Daalen, Amanda Fabra-García +11
    PLOS PathogensPeer-reviewedCC BY 4.0Full textGeneral biochemistryCell biologyPLOSPMC
  2. Targeting the Cav1.2-KCa1.1 axis prevents rabies virus internalization and protects against lethal infection
    Ziruo Sun, Jinqiu Wang, Zhiyuan Wen +16
    PLOS PathogensPeer-reviewedCC BYFull textBiophysicsPhysiologyPLOSEurope PMC
  3. A commensal-derived sugar protects against obesity by regulating immunometabolism
    Chin Yee Tan, Yinghui Li, Danting Jiang +3
    Cell host & microbePeer-reviewedLicence not statedFull text2 citedMolecular biology & gene regulationPMC
  4. CST-Polα/primase, backed up by Rif1, protects telomeric ss-dsDNA junctions from damage recognition and resection
    Eun Young Yu, Kimberly Calugaru, Tenzin Younten +2
    bioRxivPreprintAll rights reservedFull textMolecular biology & gene regulationbioRxivPMC
  5. B Cell Deficiency Protects Against the Development of c‐MET and Beta‐Catenin Driven Hepatocellular Carcinoma in Mice
    Fang Wang, Eun Bi Lim, Rehan Mehta +1
    Cell biology internationalPeer-reviewedCC BY-NC-NDFull textGeneral biochemistryEurope PMC
BibTeX
@article{arroyo2026spike,
  title = {{Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection}},
  author = {Kayla R. Arroyo and Shengnan Qian and Hansam Cho and Xiaoqing Guan and Qian Liu and Parisa Darvishi and Lanying Du},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = nov,
  doi = {10.3390/ijms272210225},
  url = {https://www.mdpi.com/1422-0067/27/22/10225},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Spike mRNA Encoding JN.1-RBD Elicits Broad Omicron-Neutralizing Antibodies and Protects Against Infection
AU  - Kayla R. Arroyo
AU  - Shengnan Qian
AU  - Hansam Cho
AU  - Xiaoqing Guan
AU  - Qian Liu
AU  - Parisa Darvishi
AU  - Lanying Du
PY  - 2026
DA  - 2026/11/15
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms272210225
UR  - https://www.mdpi.com/1422-0067/27/22/10225
AB  - Severe acute respiratory syndrome 2 (SARS-CoV-2), the single-stranded RNA virus responsible for Coronavirus Disease 2019 (COVID-19), continues to circulate globally, with the emergence of antigenically distinct variants posing ongoing challenges to vaccine effectiveness. In particular, Omicron subvariants harbor numerous mutations in the receptor-binding domain (RBD), which contribute to immune evasion and reduced susceptibility to neutralization by antibodies. Previous COVID-19 mRNA vaccines encoding the spike (S) protein of the ancestral SARS-CoV-2 or early variants of concern have demonstrated limited efficacy against Omicron subvariants, underscoring the need for next-generation vaccines capable of eliciting broad-spectrum neutralizing antibodies against Omicron and providing cross-protection against antigenically distinct variants. In this study, we designed an mRNA vaccine encoding a conserved Omicron-S backbone incorporating the JN.1 RBD (S-JN1-RBD), formulated the mRNA with lipid nanoparticles (LNPs), and evaluated its neutralizing activity and protective efficacy. This mRNA-LNP formulation exhibited an appropriate particle size and high thermal stability. It elicited cross-reactive antibodies against S proteins harboring diverse Omicron-RBDs, resulting in broad neutralizing activity against multiple pseudotyped and authentic SARS-CoV-2 Omicron subvariants. Importantly, this vaccine conferred cross-protection against challenge with the heterologous, antigenically divergent XBB.1.5 Omicron subvariant in human angiotensin-converting enzyme 2-transgenic mice. Furthermore, passive transfer of immune sera protected mice against infection with the Omicron-KP.3 subvariant, providing additional evidence of the vaccine’s broad protective potential. These findings underscore the potential of the designed mRNA immunogen to elicit broad-spectrum neutralizing antibody responses and to confer cross-protection against diverse and emerging SARS-CoV-2 subvariants.
SN  - 1422-0067
ER  -